Prediction: This Will Be Rigetti Computing's Stock Price in 1 Year

Rigetti’s stock has fallen more than 70% from its $56.34 record high and now trades near $16, while the company remains deeply unprofitable with net losses widening to $216.2 million in 2025. Analysts see revenue rising to $23.6 million in 2026 and $44 million in 2027, but the stock still implies a rich 126x 2027 sales multiple at a $5.5 billion market cap. The article argues the shares could stagnate or decline as Rigetti faces tough competition from IonQ and IBM.

Analysis

The market is still pricing RGTI like a scarce platform winner, but the setup looks more like a pre-scale infrastructure name with no operating leverage yet. The key second-order issue is that quantum remains a capital-intensity story, so every incremental dollar of “growth” that comes from one-off systems or government work is less valuable than a recurring software-like multiple would imply. That makes the current valuation vulnerable not just to slower revenue, but to any sign that commercialization continues to arrive in lumpy bursts rather than a durable install base.

The competitive dynamic is unfavorable because the category leader is not a single pure-play; it is a field where adjacent balance-sheet giants can subsidize R&D longer and bundle quantum with broader cloud/enterprise relationships. That matters for customer acquisition cost and retention: if buyers can access comparable capability through larger platforms, smaller players must spend more to defend each deal, which extends the path to operating leverage. In that environment, the real risk is multiple compression before fundamentals inflect, not just another quarter of weak top-line prints.

The main catalyst path is still binary and probably 6-18 months out: evidence of repeatable system shipments, higher utilization of remote access capacity, and a clearer conversion from pilot demand to contractual backlog. If that does not appear by the next few reporting cycles, the stock can remain range-bound or drift lower even if the broader quantum narrative stays hot. The contrarian view is that the selloff may be partly justified, but not necessarily because the technology fails—rather because the market is overestimating how quickly technological progress translates into monetizable demand.

Relative positioning favors companies with either diversified monetization or stronger balance sheets. IONQ looks less fragile on narrative momentum, while IBM has the cheapest optionality on long-duration quantum spend because it can absorb delays without rerating risk. NVDA is a weak indirect beneficiary only if quantum accelerates demand for classical AI infrastructure around simulation and error correction; otherwise the read-through is minimal.

Key Decisions for Investors

• Avoid initiating new long exposure in RGTI into the next earnings window; wait for proof of recurring backlog conversion or a pullback that resets valuation below 100x forward sales equivalent on 2027 estimates.
• Pair trade: short RGTI / long IBM over the next 3-6 months to express the view that diversified incumbency outlasts pure-play pre-scale risk; target a 20-30% relative spread if quantum enthusiasm cools.
• For more tactical exposure, use RGTI call spreads only after a shipment/backlog surprise and after the implied vol resets lower; otherwise the bleed from multiple compression outweighs upside convexity.
• Prefer IONQ over RGTI as the cleaner momentum trade in the space, but size modestly and treat it as a 1-2 quarter sentiment trade rather than a fundamentals compounder.
• If holding NVDA for unrelated reasons, do not add on the quantum thesis alone; the earnings linkage is too remote to justify paying for an incremental story with low near-term monetization probability.